Pamela Hoffman is the president and recently appointed CEO of Padagis, a US-based generic pharmaceutical company established following the divestiture of Perrigo’s generics business. With manufacturing operations in Minnesota and Israel and a portfolio of over 330 SKUs, Padagis has built its reputation as a market leader in generic extended topicals and nasal products. In this interview, Hoffman discusses the company’s international expansion into Europe, its strategic investment in US-based naloxone manufacturing capacity, and the structural challenges facing the generics sector, from pricing pressure and patent thickets to supply chain resiliency and the need for policy reform.
Can you give us an introduction to the history of Padagis as an organization today and its footprint in the US generics space?
Padagis came about through a divestiture of Perrigo’s generic business to Altaris Capital Partners in 2021. Prior to that, the generic business was formed through the combination of two companies Perrigo had acquired: Agis Industries in Israel and Paddock Laboratories in Minnesota. So while Padagis as a standalone entity is young, the underlying business is not. We are well established in the generics market and have been a player there for quite some time.
Overall, our commitment has always been to reducing healthcare costs and improving accessibility. We are the market leader in generic extended topicals, and more recently we have established ourselves as a leader in nasal products as well. We also have a history of being first to market with new dosage form generics. We have several first launches in our history, which reflects the innovation our team has consistently brought to the space.
Today, we market over 330 SKUs, manufacture in Israel and Minnesota, and employ just over 1,300 people worldwide. We primarily serve the US retail market, including with naloxone as an OTC product, and we work across government and harm reduction channels to improve access and affordability. We also have a small distribution business in Israel.
You were recently appointed CEO of Padagis, having served as president through the transition from Perrigo. Can you introduce yourself and share your priorities for the company’s next chapter?
I have over 20 years of experience in the healthcare industry. I started my career in public accounting with Arthur Andersen and later spent some time with EY. I then moved into the healthcare industry, joining Stryker before eventually moving to Perrigo. At Perrigo I held various roles, primarily in finance and compliance, before making the move to Padagis.
Throughout that journey, what kept me in healthcare was the sense that what we do makes a difference. Generics, and even Perrigo’s OTC business before it, is really about bringing affordability and accessibility to patients and consumers. Therefore, as CEO, my priority is to ensure Padagis continues to develop, manufacture, and commercialize the generic products patients need. Affordability and accessibility are critical issues in the US right now, and being able to contribute to that is rewarding.
Beyond that, I want to expand the channels through which we offer our products. Today we operate primarily in the retail market through wholesalers, but we have a broad portfolio spanning dermatologics, nasal sprays, creams, liquids, lotions, ointments, and gels. I also believe there is real opportunity in telehealth, direct-to-consumer, and international markets.
The third priority is expanding our manufacturing and development capabilities. We currently have strong in-house production in dermatologics and nasal products. From a long-term perspective, I think vertical integration is essential to surviving and growing in this industry. For us, that means identifying the next growth area and investing in the more complex dosage forms that will define Padagis’ future.
With over 330 SKUs spanning topicals and nasal sprays, how do you balance the portfolio and where do you see the priority growth areas?
Nasal sprays are more complex as a category, and we have both single-dose and multi-dose formats, with other forms under evaluation. For me, it really comes down to the product and where the need is for the patient.
We actually entered nasal sprays through migraine, which is where a lot of the initial development came from, and then expanded into naloxone. Naloxone has become a much bigger product than we ever anticipated. When we moved into opioid overdose, I could not have imagined the level of sales we would see, and that is a direct reflection of the crisis we are living through.
Naloxone is now a major focus for us because of the scale of the need. It is a life-and-death drug, and it speaks directly to the affordability and accessibility mission at the core of what we do. Prices dropped significantly when generic naloxone came to market roughly three years ago. It is sad to think that someone could have died from an overdose simply because they could not afford the medication, and I think generics have genuinely changed that picture.
The encouraging sign is that over the last two years, overdose rates have dropped. While overdoses are still occurring, we are saving more people, and I truly believe greater accessibility to naloxone is a significant part of that.
What are the significant challenges facing generic manufacturers in the US today, and what policy changes would you like to see to ensure the sector remains sustainable?
First, I want to acknowledge that generics do not exist without brand innovation. Nobody wants to prevent brands from bringing new products to market, but that does not mean we need to enable a monopoly indefinitely either.
Generics are critical to reducing healthcare costs and improving accessibility. The pricing pressure and reimbursement dynamics we face are among the biggest challenges in the industry. As competition enters a market, price pressure intensifies to a point that becomes unsustainable. We have a product in our own portfolio that has seen 13 approvals for the same drug, and today there are only three or four active players left. That churn tells you everything. Insurers and pharmacies want cheap drugs, and I understand that, but at some point prices become too cheap and generic companies exit the market. It is not reasonable to expect generic manufacturers to operate at a loss.
There is a statistic from the Association for Accessible Medicines (AAM) that showcases the scale of the problem: 20 years ago, the top 15 drugs represented the same market value as the entire generic sector. Today, it is one or two products, the GLP-1s, that carry the same value as the generic market. Something has to be done about pricing. Other countries have found ways to keep generic prices low without driving manufacturers out of the market, and I think the US could learn from some of those models.
The other major issue is market consolidation and vertical integration across wholesalers, group purchasing organizations, pharmacies, and pharmacy benefit managers. When you trace where a dollar goes in this system, the manufacturer retains somewhere around 10 to 12 percent. The rest is spread out across the different hands of the chain. Finding a way to keep more with the manufacturer is essential to long-term sustainability, and while it will be a difficult structural change that not every player in the chain will welcome, it has to happen.
The last challenge is patents. We file a number of Paragraph IV certifications, and patent litigation is expensive. Branded companies continue to layer on patent thickets, so you can win one challenge and face two, three, or even 15 more. The practical result is settlements that delay generic entry by four, five, six, or seven years. That keeps healthcare costs high, limits accessibility, and does nothing for affordability.
The Section 232 tariff exemption for generics and biosimilars was a significant recent development. Do you see it as a win for the sector, and does it signal greater recognition from policymakers of the value generics bring?
Section 232 was a huge win. When I think about the effect tariffs would have had on our business specifically, it would have been substantial. It would have raised serious questions about whether we could continue operating, and if we had, it would have been at a much lower profitability level. It was a huge relief when we learned we were exempt, and it gave me confidence that we could keep going.
While I think we are getting there in terms of recognition and awareness of what generics bring to the healthcare system and to patients, there still needs to be a lot of education. The AAM is doing a really good job of helping people understand the value generics bring, but in my own family conversations when I talk about generics, all people think of is a $4 drug at Walmart. It is great that generics make medication accessible and affordable, but they also do so much more than that. When a new generic comes to market, people get excited because they know the price is coming down. However, they do not realize how difficult it is to bring a generic to market.
If we can stop the race to the bottom on price and find a sustainable level to operate, that will help. Still, educating the public and policymakers on the value that generics bring remains critical. There are very few industries that can say they have saved patients over USD 400 billion in a single year.
Can you walk us through Padagis’ manufacturing footprint, the recent investment in US-based naloxone production, and what that commitment represents for domestic supply chain resiliency?
We were excited to make the investment in our Minnesota site with a new high-speed single-dose nasal spray line. While we have the same line in Israel, there were a few strategic reasons behind the decision. A core part of it was to underscore our commitment to US patients and the healthcare system. Naloxone is a life-saving drug that needs to be available whenever it is needed and having that production closer to home was something we felt we had to do.
This is cutting-edge technology that will significantly expand our US manufacturing capacity. It will almost double our output at the Minnesota site and positions us well to meet rising demand for high-quality nasal drug delivery systems. It also gives us redundant capability and reduces our reliance on overseas production. The geopolitical environment today is very different from what it was ten years ago so we have to be smart and forward-thinking about that.
We started this investment roughly two years ago. It takes time to procure, install, and qualify equipment of this kind, but supply chain resiliency was central to the rationale. Naloxone is a product we cannot afford to be out of stock on.
Beyond naloxone, we also see nasal as a preferred dosage form in general. Patients may prefer it over an injection where applicable, and we have products in the pipeline that reflect that trend.
The way we have configured our line is also different from how others have approached similar investments. It allows us to be cost competitive in the US while maintaining the high-quality standards that drug manufacturing demands. Quality is not negotiable when it comes to products going into somebody’s body.
Is there a perception advantage to US-manufactured generics in international markets, and is that part of the rationale for Padagis’ international expansion?
The first thing that really drove our international thinking was a simpler question: do we have medicines that patients need? We were honestly surprised by the answer. We have a large portfolio focused on dermatological products and nasal, and when we started talking to third parties, we found there was real demand for it. We had assumed other companies were fulfilling that need, but we were pleasantly surprised to find that was not the case.
What we learned is that the US has almost a luxury position when it comes to medicine availability. Even though some products here can be costly, the range of what is available is significant. What surprised me is that some of those products simply do not make it into the market in other countries. There is no option to choose them. I had assumed that what we have here was available everywhere, and it is not the case. It feels good to work for a company that can help be a solution for people when they are sick.
Regarding the perception of quality, I think India is making a concerted effort to improve, but I am not sure they are there yet. I do not think they are visited as frequently by the FDA as a US company would be, and that playing field needs to be levelled. That said, there is real value attached to US-made medicines because of the quality expectation that comes with them, and in some markets we do see that. Customers want to know they are getting that quality, and it matters to them.
What does Padagis’s international expansion look like in practice? How are you approaching portfolio development and market entry?
The international strategy really is country and product specific. We look at the data, identify what is not available in a given market, and see if we have a product to fit that need. We have been pleasantly surprised, particularly with topicals. Products that we have been using in the US for years, or even decades, are simply not available as generics in other markets. That has been an eye-opener.
In Europe, the focus has been primarily on dermatologics, but also on hormone replacement therapy. We have a product we have been selling in the US for ten years that we are now selling in the UK on a conditional basis, and we intend to be the first to register it there formally. It speaks to a broader pattern in which the rest of the world is catching up to where the US has been, and there is a delay between what is available here and what reaches other markets.
For naloxone, the US is more aware of the opioid crisis and, I would say, less reluctant to confront it publicly. What we hear from conversations in other countries is a different story. Harm reduction agencies recognize the problem, but at a government level there can be a reluctance to acknowledge that overdoses are an issue. While it might just take time to get there, the desire to not admit that there is a potential problem will hurt patients in the long run. That said, we now have a marketing authorization for naloxone in several European countries and are looking forward to launching there in 2026.
Overall, the portfolio we are taking internationally is focused on dermatologics, a couple of nasal products, and naloxone. Where we see a need in the market, we try to put the product there to improve access.
Looking at the next few years, what is the broader strategic direction for Padagis?
Given our prior focus on extended topicals and nasals, the first priority is broadening our product portfolio. Hormone replacement therapy is one area we are actively considering. It is a growing market, but also an incredibly complex one. Hormones cannot be manufactured just anywhere, and finding suppliers is difficult. We already manufacture hormones in Israel and have the proper facilities and procedures in place, so it is a natural area for us to develop further.
Alongside that, we are investing in advanced manufacturing. We have already put significant investment into our Israel site and more recently our Minnesota site, focused on robotics and automation. When you can run a line with one or two people rather than the 15 or 20 it would have taken previously, it brings your cost structure much closer to what a low-cost country can offer. That kind of efficiency is what allows us to remain competitive while manufacturing in the US.
Supply chain resiliency is the third priority. The geopolitical environment, and the situation in Israel specifically, has reinforced the importance of that. Our team there has been remarkably resilient and we have had no operational impact over the past couple of years, but we want to be prepared. US manufacturing is central to that strategy. Minnesota is our primary focus and I expect to see further expansion there over the next one to three years with new highly automated lines.
The last piece is continuing to support the AAM on policy reform. Our goal is to be here long term and to be a generic company that contributes to the good of society. To do that, we need policy reform. Progress will not come overnight, but I think bit by bit we will get to a place where we have a sustainable business model that works.
What is your final message to the stakeholders, policymakers, and healthcare players about the importance of the role that generic manufacturers like Padagis play in creating long-term system sustainability?
I want people to know that Padagis is a committed partner in America’s healthcare journey. We are incredibly proud to play the role we do in delivering affordable and accessible medicines. My employees come to work knowing they are making a difference, and that matters. Despite the pressures weighing on the generics market, Padagis will continue to invest in innovation, domestic production, and supply chain stability to ensure we are here for the long term and can continue giving patients the medicines they need.

